Cognition Therapeutics Inc (CGTX) Stock Price, Quote & News

Company Profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as ge...

Industry: Biotechnology

Sector: Healthcare

Phone: 412 481 2210

Website: www.cogrx.com

Address:

2500 Westchester Ave., Purchase, United States

BarryLong28 Aug. 7 at 10:16 PM

$CGTX I love quiet boards. Let’s hope leadership pulls this off!

1 · Reply

nostic Aug. 7 at 10:04 PM

$CGTX this is my understanding of the calendar set up here... the company expects to get a Phase 3 approval "later this month" and a FDA decision on the BTD application "in Q3-2025" (so by end of September at the latest). While their compliance deadline is September 8, they can appeal that and the stock keeps trading. This would buy them another 30 to possibly even 60 days, which would be enough time to get the BTD decision. And there's a possibility they might arrange a partnership deal ahead of the final NASDAQ hearing deadline. So bottom line, even if we aren't in compliance by 9/8 and haven't heard on BTD or partnership, there's still another month or two of time.

1 · Reply

HeekLikeThis Aug. 7 at 9:57 PM

$CGTX They're very confident about the upcoming FDA news. Guys, we're going to make a lot of money here.💚🍀

0 · Reply

HeekLikeThis Aug. 7 at 9:48 PM

$CGTX If they don't file an 8-K or an official press release about a reverse split tomorrow, there's virtually no logistical window left to do it in time before August 25th, which is the 10-day trading day on the Nasdaq to be above $1. The company is over-tightening, I'm pretty sure it's for a good reason, and we'll have big news tomorrow that will send the price to $1 without RS.💚🍀

1 · Reply

aletz Aug. 7 at 9:21 PM

$CGTX Zero mention nor concern about RS, cannot be a baseless confidence.

0 · Reply

aletz Aug. 7 at 9:18 PM

$CGTX First time to release earnings in the afternoon, something big is coming soon.

1 · Reply

ROMEO44 Aug. 7 at 8:59 PM

$CGTX This is like a no brainer all in buy -----soon 1$ ++++++++

0 · Reply

FitzCatalyst Aug. 7 at 8:44 PM

$CGTX so the fact nothing was said about rs… is pretty wild. They seem to be very confident about where the stock price will be next month..(not two months. Literally one more month)…sounds like (no promises) that once phase 3 layout is confirmed, a partnership will be announced.

0 · Reply

Dmsrz8 Aug. 7 at 8:27 PM

$CGTX so, what we now know is this: 1. We will know in the next two weeks about FDA feedback on Alzheimer’s P3 2. We will know no later than end of Q3 (Sept) on FDA decision for breakthrough status for DLB These are the two big catalysts. Both can create massively viable opportunities for partnership and or buyout, if positive. Lastly, the cash runway is now extended into Q2 of 26’. I was happy to see this. It means they likely ran the ATM to buy more time to get funding or get bought out. They were smart with it and made sure not to suppress for too long. I like how they did this.

0 · Reply

DiamondHands4daWin Aug. 7 at 8:26 PM

$CGTX https://ir.cogrx.com/press_releases/cognition-therapeutics-reports-financial-results-for-the-second-quarter-2025-and-highlights-progress-across-clinical-programs/

0 · Reply

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease

Jul 21, 2025, 7:30 AM EDT - 17 days ago

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease

Jul 16, 2025, 7:30 AM EDT - 22 days ago

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

Jul 10, 2025, 7:30 AM EDT - 4 weeks ago

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease

Jul 1, 2025, 7:30 AM EDT - 5 weeks ago

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target

Jun 25, 2025, 7:30 AM EDT - 6 weeks ago

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)

Jun 3, 2025, 7:30 AM EDT - 2 months ago

Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

May 28, 2025, 7:30 AM EDT - 2 months ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies

May 9, 2025, 7:30 AM EDT - 3 months ago

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

May 7, 2025, 7:30 AM EDT - 3 months ago

Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

Apr 1, 2025, 7:30 AM EDT - 4 months ago

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes

Mar 25, 2025, 7:30 AM EDT - 4 months ago

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025

Mar 20, 2025, 1:15 PM EDT - 5 months ago

Cognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 7:00 AM EDT - 5 months ago

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

Mar 13, 2025, 4:05 PM EDT - 5 months ago

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

Mar 12, 2025, 4:05 PM EDT - 5 months ago

Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing

Mar 10, 2025, 7:30 AM EDT - 5 months ago

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

Feb 27, 2025, 7:30 AM EST - 5 months ago

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

Feb 25, 2025, 7:30 AM EST - 5 months ago

Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

Jan 30, 2025, 7:30 AM EST - 6 months ago

Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

Jan 8, 2025, 4:14 PM EST - 7 months ago

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

Dec 18, 2024, 11:06 AM EST - 8 months ago

Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?

Dec 18, 2024, 7:22 AM EST - 8 months ago

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

Nov 26, 2024, 7:30 AM EST - 9 months ago

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

Nov 25, 2024, 7:30 AM EST - 9 months ago

Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population

Nov 13, 2024, 7:30 AM EST - 9 months ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

Nov 12, 2024, 7:30 AM EST - 9 months ago

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

Oct 31, 2024, 4:15 PM EDT - 10 months ago

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

Oct 29, 2024, 12:55 PM EDT - 10 months ago

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Oct 23, 2024, 7:30 AM EDT - 10 months ago

Analyses from Cognition's Positive Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD

Oct 22, 2024, 7:30 AM EDT - 10 months ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

Oct 2, 2024, 7:30 AM EDT - 11 months ago

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

Oct 1, 2024, 7:30 AM EDT - 11 months ago

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

Aug 22, 2024, 7:31 AM EDT - 1 year ago

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease

Aug 11, 2024, 12:55 AM EDT - 1 year ago

Cognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Report Second Quarter 2024 Financial Results

Jul 29, 2024, 7:14 AM EDT - 1 year ago

Cognition Therapeutics announces positive results from trial of oral treatment for mild-to-moderate Alzheimer's disease

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Cognition Therapeutics' Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer's Patients

Jul 26, 2024, 4:11 PM EDT - 1 year ago

Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at 8:30am ET on Monday July 29, 2024

Jul 2, 2024, 7:30 AM EDT - 1 year ago

Results from Cognition Therapeutics' Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease Accepted for Presentation at AAIC

May 21, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease

May 7, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update

Apr 29, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

Apr 22, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease

Apr 2, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference

Apr 1, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024

Mar 26, 2024, 12:02 PM EDT - 1 year ago

Cognition Therapeutics, Inc. (CGTX) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:00 AM EDT - 1 year ago

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

BarryLong28 Aug. 7 at 10:16 PM

$CGTX I love quiet boards. Let’s hope leadership pulls this off!

1 · Reply

nostic Aug. 7 at 10:04 PM

1 · Reply

HeekLikeThis Aug. 7 at 9:57 PM

$CGTX They're very confident about the upcoming FDA news. Guys, we're going to make a lot of money here.💚🍀

0 · Reply

HeekLikeThis Aug. 7 at 9:48 PM

1 · Reply

aletz Aug. 7 at 9:21 PM

$CGTX Zero mention nor concern about RS, cannot be a baseless confidence.

0 · Reply

aletz Aug. 7 at 9:18 PM

$CGTX First time to release earnings in the afternoon, something big is coming soon.

1 · Reply

ROMEO44 Aug. 7 at 8:59 PM

$CGTX This is like a no brainer all in buy -----soon 1$ ++++++++

0 · Reply

FitzCatalyst Aug. 7 at 8:44 PM

0 · Reply

Dmsrz8 Aug. 7 at 8:27 PM

0 · Reply

DiamondHands4daWin Aug. 7 at 8:26 PM

$CGTX https://ir.cogrx.com/press_releases/cognition-therapeutics-reports-financial-results-for-the-second-quarter-2025-and-highlights-progress-across-clinical-programs/

0 · Reply

Dmsrz8 Aug. 7 at 8:22 PM

$CGTX The Company estimates that it has sufficient cash to fund operations and capital expenditures into the second quarter of 2026.

0 · Reply

DiamondHands4daWin Aug. 7 at 8:20 PM

$CGTX

0 · Reply

Dmsrz8 Aug. 7 at 8:18 PM

$CGTX “Later this month we anticipate receiving the FDA’s minutes from our end-of-Phase 2 meeting regarding registrational plans for zervimesine in Alzheimer’s disease. We expect these will confirm our understanding of the Agency’s expectations for a clinical program in Alzheimer’s disease,” added Ms. Ricciardi. “In addition, we expect FDA will have a decision on breakthrough designation for zervimesine in DLB in the third quarter 2025. We expect these milestones will be valuable to potential partners as we continue to evaluate our options to support development of zervimesine.”

0 · Reply

FitzCatalyst Aug. 7 at 8:16 PM

$CGTX so nothing about rs?

1 · Reply

DiamondHands4daWin Aug. 7 at 8:14 PM

$CGTX https://ir.cogrx.com/press_releases/cognition-therapeutics-reports-financial-results-for-the-second-quarter-2025-and-highlights-progress-across-clinical-programs/

0 · Reply

MrTicker Aug. 7 at 8:11 PM

$CGTX Cognition Therapeutics Q2 net loss narrows to $6.7 mln REUTERS 3:10 PM ET 8/7/2025 Overview * Cognition Therapeutics(CGTX) reports Q2 net loss of $6.7 mln, slight improvement from 2024 * Company surpasses 50% enrollment in Phase 2 Alzheimer's study * Positive results from dry AMD study with 28.6% reduction in lesion growth Outlook * Company anticipates FDA decision on DLB breakthrough designation in Q3 2025 * Cognition sees FDA milestones aiding potential partnerships for zervimesine Result Drivers * ALZHEIMER'S STUDY - Surpassed 50% enrollment in Phase 2 study of zervimesine in early Alzheimer's disease * DRY AMD RESULTS - Reported 28.6% reduction in geographic atrophy lesion growth in Phase 2 dry AMD study * DLB PROGRAM - Initiated expanded access program for dementia with Lewy bodies

0 · Reply

MrTicker Aug. 7 at 8:01 PM

$CGTX Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs GLOBENEWSWIRE 3:00 PM ET 8/7/2025 - Discussed plans to support a pivotal Alzheimer’s disease program with FDA at end-of-phase 2 meeting - - Initiated expanded access program (EAP) for people with dementia with Lewy bodies (DLB) - - Surpassed 50% enrollment in Phase 2 ‘START’ study of zervimesine in early Alzheimer’s disease -

1 · Reply

DLBEE Aug. 7 at 7:13 PM

$CGTX Is she going to announce reverse split after close today?

1 · Reply

Silvercaine Aug. 7 at 6:33 PM

$CGTX Technicals turned to utter sh*t. 100MA is holding but otherwise does not look good. My previous post when it was good, was for short term. Monthly is exhilarating at the moment. Around 7.5 million of float is shorted and off exchange is sky high. This REALLY need that catalyst to be good🤔

0 · Reply

nostic Aug. 7 at 6:16 PM

$CGTX pay-tience and four-titude

0 · Reply

Itinerant Aug. 7 at 5:34 PM

$CGTX Will the company have important good news for us today? I hope so. What do you think?

1 · Reply

Dmsrz8 Aug. 7 at 4:58 PM

$CGTX should end up just fine.

1 · Reply

Market Cap	44.08M
Revenue (ttm)	0.00
Net Income (ttm)	-33.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,736,600
Avg Vol	9,150,748
Day's Range	N/A - N/A
Shares Out	61.99M
Stochastic %K	41%
Beta	1.00
Analysts	Strong Sell
Price Target	$3.25